Clinical-stage radiopharmaceutical company Oncoinvent ASA (Euronext Growth Oslo:ONCIN) on Monday announced updated 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis.

The trial, which closed for recruitment at the end of 2023, is now in long-term follow-up.

In the study, 10 patients received a single intraperitoneal dose of 7 MBq Radspherin. At the 12-month follow-up reported in November 2024, only one patient had experienced peritoneal recurrence.

The 18-month data showed no new recurrences, maintaining the recurrence rate at 10%. In comparable populations treated with best standard of care, approximately 40% of patients would typically have had a recurrence by this stage.